SyVento BioTech is a biotechnology company offering comprehensive services in the development of lipid-based nanocarriers and LNP technology. We specialize in the development of lipid-based formulations for pharmaceutical products, including RNA-based drug products.
Genetic platform
SyVento BioTech’s R&D Team offers technical and scientific support throughout the entire process, including advice on troubleshooting and optimization of RNA synthesis conditions. Our RNA synthesis proficiency guarantees successful results in downstream applications.
By incorporating these important features, our genetic platform for RNA synthesis
provides:
Delivery platform
Our Team’s qualifications and experience provide a wealth of expertise in the development of lipid-based delivery systems.
SyVento BioTech’s LNP delivery systems:
Manufacturing platform
Our capabilities offer the possibility of scaling the production of formulations based on lipid nanocarriers by transferring solutions developed in the laboratory on a semi-technical and technical scale.
Thanks to the extensive equipment base, we are able to perform:
Drug development expertise
June 6, 2023
Aktualizacja Siedziby SyVento Sp. z o.o. / Change of Registered Office of SyVento sp. z o.o.Jest nam niezmiernie miło poinformować, że SyVento Sp. z o.o. z dniem 5 czerwca 2023 roku oficjalnie przenosi swoją siedzibę. Nowy adres wpisany do Krajowego Rejestru Sądowego przez Sąd Rejestrowy to: ul. Za Górą 19, 32 – 050 Skawina. Ta zmiana jest bezpośrednim wynikiem naszej inwestycji w Centrum Badań i Rozwoju Biotechnologicznego w Skawinie oraz […]
June 6, 2023
SyVento BioTech Attends BIO International Convention 2023SyVento BioTech Attends BIO International Convention 2023 SyVento BioTech is currently participating in the BIO International Convention 2023. The organization’s representatives at this event are Business Development Manager Dr. Oskar Szelest, R&D Director Dominik Lipka, PhD Eng., and Chairman of the Supervisory Board, Tomasz Piec. This convention is hosting over 15,000 biotechnology and pharmaceutical leaders […]
March 13, 2023
RNA Leaders Europe Congress – Meet us at stand 16Tomasz Piec, President of Supervisory Board, Dominik Lipka, PhD Eng., Director of Research and Development, Board Member, and Oskar Szelest, PhD, Business Development Manager, will be attending this year’s RNA Leaders conference.
December 9, 2021
SyVento and OncoArendi agreementSyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02. Details in following press release.
November 16, 2021
Thank you for exciting time during 9th International mRNA Health ConferenceDuring the past days, we looked at the exciting field of mRNA from different perspectives & gotten insights into the current research. It was a pleasure being with you.
October 30, 2021
Join & Meet us at 9th Annual International mRNA Health ConferenceWe are looking forward to exploring the rapidly advancing mRNA technology together with other conference participants during 9th Annual International mRNA Health Conference.
Let's collaborate and create quality liposome encapsulated drugs together.
